Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ECT Clear all
Completed Phase 2 Interventional Results available

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

NCT01530659
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Usher Syndrome Type 3
Interventions
NT-501, Sham
Drug · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 17, 2026, 6:09 PM EDT
Recruiting Not applicable Interventional

Amplitude Titration to Improve ECT Clinical Outcomes

NCT05699226
View directory record Official record
Conditions
Depression, ECT, Cognitive Change
Interventions
Soterix Medical Incorporated 4x1 adapter, Traditional ECT device
Device
Lead sponsor
University of New Mexico
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)

NCT01441960
View directory record Official record
Conditions
Neuromuscular Blockade, ECT
Interventions
Succinylcholine, Rocuronium
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

NCT00447954
View directory record Official record
Conditions
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions
High Dose NT-501 implant, Low Dose NT-501 implant, Sham
Combination Product · Other
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 17, 2026, 6:09 PM EDT
Terminated Not applicable Interventional

Efficacy and Safety of Low Amplitude Electroconvulsive Therapy

NCT02351843
View directory record Official record
Conditions
Depression
Interventions
MECTA Spectrum 5000Q
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 17, 2026, 6:09 PM EDT
Withdrawn Early Phase 1 Interventional

Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT

NCT06733558
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder II
Interventions
Electroconvulsive Therapy
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional

Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy

NCT01876758
View directory record Official record
Conditions
Memory Deficits, Electroconvulsive Therapy
Interventions
Cognitive Intervention: Memory Training, Comparable general mental stimulation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 17, 2026, 6:09 PM EDT
Withdrawn Phase 1 Interventional

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

NCT03895658
View directory record Official record
Conditions
Unipolar Depression
Interventions
MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 17, 2026, 6:09 PM EDT
Completed No phase listed Observational

Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy

NCT00209066
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 17, 2026, 6:09 PM EDT
Not listed Not applicable Interventional

Neural Biomarkers of Electroconvulsive Therapy Response

NCT04763655
View directory record Official record
Conditions
Electroconvulsive Therapy Treated Patients
Interventions
clinical and neuropsychological testing
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

NCT01397825
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
Interventions
Alisertib (MLN8237), Rituximab, Vincristine
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Burbank, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 17, 2026, 6:09 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?

NCT00988663
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
memantine, Placebo
Drug
Lead sponsor
Jerrry L Lewis
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Not applicable Interventional Results available

Electroconvulsive Therapy Amplitude Titration

NCT04621786
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
Device
Lead sponsor
University of New Mexico
Other
Eligibility
50 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults

NCT01869374
View directory record Official record
Conditions
Depression, Major Depressive Episode, Bipolar Disorder
Interventions
MagVenture MagPro MST, RUL ECT
Device · Biological
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 17, 2026, 6:09 PM EDT
Terminated Phase 4 Interventional

Use of Risperidone in ECT for Treatment Resistant Depression

NCT00203723
View directory record Official record
Conditions
Major Depression
Interventions
Risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 17, 2026, 6:09 PM EDT
Recruiting Phase 1 Interventional

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

NCT06312748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Inflammation
Interventions
L-Citrulline, Placebo for L-Citrulline, BH4, Placebo for BH4, Atorvastatin, Placebo for Atorvastatin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 6:09 PM EDT
Enrolling by invitation Phase 4 Interventional

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

NCT06034821
View directory record Official record
Conditions
Acute Suicidal Depression (ASD)
Interventions
Subanesthetic dose intravenous ketamine (KET), Electroconvulsive therapy (ECT)
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
9
States / cities
San Francisco, California • Baltimore, Maryland • Belmont, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 17, 2026, 6:09 PM EDT
Active, not recruiting Not applicable Interventional

CET- REM (Correlating ECT Response to EEG Markers)

NCT04451135
View directory record Official record
Conditions
ECT, Treatment Resistant Depression
Interventions
Electroencephalographic (EEG), Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16), Ictal Electroencephalographic (EEG) Measurements, Post-Ictal Electroencephalographic (EEG) Suppression Measurements
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 1 Interventional Results available

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

NCT01898078
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
The Bronx, New York • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 4 Interventional Results available

ECT Pulse Amplitude and Medial Temporal Lobe Engagement

NCT02999269
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
MECTA Spectrum 5000Q Amplitude
Device
Lead sponsor
University of New Mexico
Other
Eligibility
50 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 4 Interventional

Prolonging Remission in Depressed Elderly (PRIDE)

NCT01028508
View directory record Official record
Conditions
Depression
Interventions
lithium and Venlafaxine, ECT
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Augusta, Georgia • Rochester, Minnesota • Hoboken, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 17, 2026, 6:09 PM EDT
Completed No phase listed Observational

MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression

NCT02044289
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 17, 2026, 6:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

NCT01045421
View directory record Official record
Conditions
Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma
Interventions
MLN8237 (Alisertib)
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 17, 2026, 6:09 PM EDT